Disclosed is an oral pharmaceutical formulation comprising (3,5-bis-trifluoromethyl)-N-[4-methyl-3-({ 4-(pyridin-3-yl)-pyrimidin-2-yl} amino)-phenyl]-benzamide (also known as NRC-AN-019) including its pharmaceutically acceptable salts and polymorphs such as Form I, Form II and Form III, as well as a lipohilic phase, a surfactant and a water miscible solvent. The formulation is intended to improve the bioavailability of NRC-AN-019 upon contact with the gastro-intestinal fluid. Also disclosed is the use of the formulation containing NRC-AN-019 in the manufactureof a medicament for the treatment of chronic myeloid leukemia and against other tumors such as head and neck cancer and prostate cancer.
